Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT)
Mucopolysaccharidosis Type IIIB (MPS IIIB / Sanfilippo Syndrome Type B)
Phase 3Investigational, active development
Key Facts
Indication
Mucopolysaccharidosis Type IIIB (MPS IIIB / Sanfilippo Syndrome Type B)
Phase
Phase 3
Status
Investigational, active development
Company
About Spruce Biosciences
Spruce Biosciences is a patient-inspired biotech focused on serious, underserved neurological and endocrine conditions, with its lead program TA-ERT targeting MPS IIIB (Sanfilippo Syndrome Type B) in Phase 3. The company emphasizes a culture of innovation, trust, and urgency, driven by a leadership team with deep clinical and operational expertise. Spruce has been recognized as a 'Best Place to Work' in the Bay Area and is actively seeking strategic collaborations to advance its mission of delivering transformative therapies.
View full company profile